- Conditions
- Generalized Anxiety Disorder
- Interventions
- ITI-1284 10 mg, ITI-1284 20 mg, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Glendale, California • Imperial, California • Lemon Grove, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 4,133
matching trials from the local directory fallback.
- Conditions
- Bipolar Depression
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 56
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo, TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 30
- States / cities
- Murrieta, California • Orange, California • Clearwater, Florida + 27 more
- Conditions
- Hemolytic Disease of the Fetus and Newborn
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Major Depressive Disorder
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 13 more
- Conditions
- Attention Deficit Hyperactivity Disorder Combined
- Interventions
- Methylphenidate, Placebo
- Drug
- Lead sponsor
- Donald Gilbert, MD, MS, FAAN, FAAP
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Obese Adults
- Interventions
- Placebo, VK2735 Drug
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Lake Forest, California • Miami, Florida
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- ORKA-002, Placebo
- Drug · Other
- Lead sponsor
- Oruka Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 12 more
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 68
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more
- Conditions
- Obesity
- Interventions
- NNC0487-0111, Placebo (matched to NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 22
- States / cities
- Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more
- Conditions
- Asthma
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Jose, California + 17 more
- Conditions
- Infertility (IVF Patients)
- Interventions
- Placebo, hMG subcutaneous injection
- Drug
- Lead sponsor
- Granata Bio Corporation
- Industry
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Encino, California • Norwalk, Connecticut • Newark, Delaware + 13 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
- Interventions
- Muvalaplin, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
- Conditions
- GM1 Gangliosidosis, GM2 Gangliosidosis, Niemann-Pick Type C Disease
- Interventions
- AZ-3102, Placebo
- Drug
- Lead sponsor
- Azafaros B.V.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
- Conditions
- Bipolar Disorder Type I With Mania or Mania With Mixed Features
- Interventions
- KarXT, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
- Conditions
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- 5-fluorouracil (5-FU), Capecitabine, Folinic acid (leucovorin or local equivalent), Oxaliplatin, Pembrolizumab, Placebo, zolbetuximab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Milsaperidone, Placebo
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 24 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- Anifrolumab (blinded), Anifrolumab (unblinded, open label), Placebo
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more
- Conditions
- Obesity, Weight Gain
- Interventions
- Placebo, Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more
- Conditions
- Cognitive Impairment, Sleep Quality
- Interventions
- Nicotinamide riboside, Placebo
- Dietary Supplement
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Buffalo, New York
- Conditions
- Children, Only, Nausea, Vomiting
- Interventions
- Inhaled Isopropyl Alcohol, Inhaled Placebo, Oral Ondansetron
- Other · Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy Controls
- Interventions
- Placebo, Sodium Hyaluronate
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Alcoholic Hepatitis
- Interventions
- Placebo, Sodium Hyaluronate
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio